Previous 10 | Next 10 |
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 PR Newswire LEXINGTON, Mass. , Feb. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948)...
2024-01-24 12:48:28 ET More on Mid-day movers $ stocks. Peraso Inc. (PRSO) Q3 2023 Earnings Call Transcript Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript Sight Sciences says Q4 total revenue i...
2024-01-12 21:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-30 08:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study PR Newswire LEXINGTON, Mass. , Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally availabl...
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference PR Newswire LEXINGTON, Mass. , Dec. 11, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an ...
Curis Announces Three Presentations at ASH PR Newswire LEXINGTON, Mass. , Dec. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, to...
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma PR Newswire LEXINGTON, Mass. , Dec. 5, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orall...
Curis, Inc. (NASDAQ: CRIS) is one of today's top gainers. The company's shares have moved 6.09% on the day to $4.18. Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage dru...
2023-11-17 10:00:08 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Curis, Emergen...
News, Short Squeeze, Breakout and More Instantly...
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024 PR Newswire LEXINGTON, Mass. , April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 62.9% to $0.0373 on volume of 466,310,671 shares INVO BioScience Inc. (INVO) rose 139.5% to $1.82 on volume of 225,666,770 shares PROSHARES TRUST (SQQQ) rose 3.7% to $11.86 on volume of 167,545,988 ...
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in ...